• Likewise, please address limitations related with the 180-day market exclusivity for first generic to enter the market
REVIEWER
Richard Croker Honorary Research Fellow, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK REVIEW RETURNED 10-Dec-2018
GENERAL COMMENTS
In general this paper is an interesting discussion about the topic of "evergreening", which will be of interest. However, I believe it needs some revision before being accepted for publication.
General comments I think more should be made of the various factors that leads to prescribing decisions being made, such as decision support tools, formulary and medicines optimisation team decisions, patient safety recommendations. One limitation of the paper is that, if cheaper products were available more quickly, take-up may have been more rapid and therefore savings may have been greater. There also needs to be a more complete description of the NHS reimbursement of medicines in primary care, especially for those readers not familiar.
Throughout the paper there seems to be confusion between "generic" (ie those marketed under the drug's chemical name) and "brands" (where it has a specific brand name, e.g. Reletrans). I would suggest that this is amended to make clear throughout the difference. For example, Page 1: Line 36 refers to "generics", when I think should be "other brands" or "branded generics". There are many other examples.
The most important issue with this paper is the definition of the data used. Thank you for the opportunity to review this study. This study used NHS business services authority data to estimate potential cost savings lost to the NHS as a results of a six month delayed entry of generic LDTB patches into the market in England related with a patent infringement litigation. This is an important and timely topic
• Authors should not use brand names but active ingredients
Response to reviewer: Thank you for your comment, you are right, we would normally only use INN names, but this article estimates the impact of the delayed entry of multiple generics as a result of originator's strategies to delay entry of generics, therefore, we think that brand names are important in such analysis to differentiate between the different products dispensed.
• Cost and saving estimations should be converted to 2016 USD Response to reviewer: Since this study estimated the savings lost for the NHS in England and the prices are listed in Sterling Pounds, we believe that it is appropriate for cost o be quoted in Sterling Pounds.
• Please explicitly state whether the 28% expenditures on generics out of a total of £17.4 billion spent in 2016-2017 refers to primary care settings only Response to reviewer: Thank you for your notice. This sentence has been amended accordingly.
• Authors used price listed in the national drug tariff to estimate potential cost savings lost to the NHS and patients. Please, state whether rebates and discounts are routinely negotiated between the NHS and the sponsor companies and thus, how listed prices may be different from NHS paid prices. If so, please explain how study findings, (i.e., estimated cost savings) may be different.
Response to reviewer: Prices listed in the NHSBSA are the cost of the drug before discounts and not including dispensing costs. This point has been added in the method section and the limitation of the study.
• Of note, authors, please notice that lost savings to the NHS are funds wasted directly impacting patients and ultimately tax payers.
Response to reviewer: We are agreeing with you, thank you for this notice. This has been added to the narrative.
• Authors could also elaborate on the bigger picture (i.e., the overall generic drug policy). For instance, generic substitution has been used only with partial success in several European countries and the opportunity lost due to the Care Quality Commission 2017 recommendation to use the brand name in the prescription, rather than the active ingredient, in spite of the national generic substitution program and the national generic first prescribing policy
•
It would be helpful to put study findings in perspective. Prior research estimated over a £1bn a year (about 10% of the total drug budget) the potential savings related with a more cost-effective generic prescribing policy In general this paper is an interesting discussion about the topic of "evergreening", which will be of interest. However, I believe it needs some revision before being accepted for publication.
Response to reviewer: Thank you for your comments. More narrative about these points have been added Throughout the paper there seems to be confusion between "generic" (ie those marketed under the drug's chemical name) and "brands" (where it has a specific brand name, e.g. Reletrans). I would suggest that this is amended to make clear throughout the difference. For example, Page 1: Line 36 refers to "generics", when I think should be "other brands" or "branded generics". There are many other examples.
Response to reviewer: This point has been addressed throughout the article
The most important issue with this paper is the definition of the data used. Table 1 suggests there being no generic buprenorphine price until August 2016, which suggests that a generic is not marketed. Although this may be the case, there was a generic price as listed in the Drug Tariff, and it is likely that there was prescribing of buprenorphine generically in this time period. The methods and results need revision to describe this, as NHSBSA cannot describe what was supplied against a prescription. Therefore Page 7, Line 56 "In contrast, Buprenorphine ® gained a high market share (58%) on entry in September 2016" does not make sense (https://openprescribing.net/analyse/#org=CCG&numIds=0407020B0AAAHAH,0407020B0AAAIAI,04 07020B0AAAKAK,0407020B0AAAJAJ&denom=nothing&selectedTab=chart) as NHSBSA does not track what was supplied.
Response to reviewer: You are right, there may be some misunderstanding since we have used "Buprenorphine®" as an unbranded generic. We have stated that branded and unbranded generic LDTB entered the market in September 2016. We have removed Buprenorphine® as a branded and just refer to it as a non braded LDTB patches.
Although the Drug Tariff had a generic price in August 2016, the NHSBSA data is based on what community pharmacies supplied against GP prescriptions, therefore, this data relates to actual LDTB patches used, which differs from Openprescribing database which did not provides an information about (or tracks) dispensed items. More information about the NHSBSA has been added to the narrative.
Is there a uniform linear price change per mg between all strengths of the patches? If so, this should be stated in the methods. If not, this table will need revision, for example to describe the uptake per strength of patch. Table 1 describes a difference between Butrans and generic buprenorphine, but the generic reimbursement price for generic LDTB has remained constant since 2001: https://openprescribing.net/tariff/?codes=0407020B0AAAIAI&codes=0407020B0AAAKAK&codes=040 health care services and pharmaceuticals Do authors simply refer to a universal coverage/national health system funded mainly through income taxes? "Generic prescribing is a standard practice in UK." Stating how much generics represent both in sales and volume of prescription drugs would be way more informative than general statements. "to prescribe generically" ? to prescribe using nonproprietary names/ to prescribe generics "This website (database) captured monthly information (drug name, dose, quantity and cost) on all medicines" Please clarify drug tariff cost "the price listed in the national drug tariff or in standard price lists is the cost of the drug before discounts and not including dispensing costs" please clarify it is not the drug cost but the tariff paid by the NHS to the sponsor company/manufacturer. Tariffs, list prices, etc. are not drug costs -these are different concepts "In 2016/2017, the NHS spent £17.4 billion on medicines in primary care" do they authors mean on outpatient pharmaceuticals? What was the response on the 180-day exclusivity?
REVIEWER
Richard Croker Honorary Research Fellow, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK REVIEW RETURNED 12-Feb-2019
GENERAL COMMENTS
Thank you for the chance to re-review this paper. Unfortunately it appears that a number of my comments were not agreed on in the revision. This means that without clarification and revision, I cannot recommend for publication.
Firstly, on second reading, I have a further concern that the data source used was ePACT2 (reference 20 This is not true, as outlined in the open-source dataset available from the NHSBSA -there is both "net ingredient cost", which is the non-discounted price, and the actual cost, which includes a national discount of approximately 7-8%, as well as other items such as container fees etc. More can be found at: https://psnc.org.uk/dispensing-supply/endorsement/discountdeduction/ Also, one addition has been made which is incorrect. Page 13, first paragraph "in primary care" has been added. This is not correctthe costs in primary care are approximately £9bn per annum.
VERSION 2 -AUTHOR RESPONSE
Reviewer(s)' Comments to Author:
Reviewer: 1 Study included data from February 2015 to January 2018. Please confirm that all pounds and cost savings calculations were converted to constant units using CPI (rather than current units). Also, due to the large distribution of the BMJ Open journal conversion to USD in constant units would be relevant to the outside of UK readers at least for the main study findings (e.g. potential savings lost).
